Author ORCID Identifier
0000-0001-8856-4625
Date of Graduation
8-2022
Document Type
Dissertation (PhD)
Program Affiliation
Biostatistics, Bioinformatics and Systems Biology
Degree Name
Doctor of Philosophy (PhD)
Advisor/Committee Chair
Nicholas Navin
Committee Member
Bora Lim
Committee Member
Ken Chen
Committee Member
Peter Van Loo
Committee Member
Scott Kopetz
Abstract
Aneuploidy is a prominent feature in Triple-Negative Breast Cancers (TNBC), however, the evolution of genotypes during tumor expansion remains poorly understood. The prevalent model of TNBC evolution is the Punctuated Copy Number Evolution (PCNE), in which tumors undergo a period of elevated genomic instability, acquiring complex genomic rearrangements within a short timeframe followed by clonal stasis. However, these observations rely on limited cell numbers and inherent experimental bias from first-generation single cell technologies. Therefore, the evolutionary trajectory after the punctuated burst remains unknown. To address this question, we sequenced 9,765 cells from 8 primary TNBCs and 6,413 cells from 4 TNBC cell lines using a novel single cell DNA sequencing method, Acoustic Cell Tagmentation. Our results show that TNBCs maintain a reservoir of subclonal diversity during expansion and go through a period of transient instability after the punctuated burst. We also demonstrate this diversity in TNBC cell lines that quickly re-diversify their genotypes. Lastly, the advances in single cell copy number methods require analytical tools that can scale up with cell throughput. To address this problem, we present CopyKit, an end-to-end tool for analyzing single cell copy number datasets. We show that CopyKit can resolve the clonal substructure of two metastatic liver samples. We also apply CopyKit to determine the metastatic lineages of a primary breast tumor with metastasis to the liver and pleural effusion and two matched colorectal carcinoma and its matched metastatic tumors.
Keywords
single cell, copy number, tumor heterogeneity, copykit, triple negative breast cancer.